Palbociclib and other CDK4/6 inhibitors, for example, are now standard treatments for breast cancer (Liu et al., 2018), and everolimus and temsirolimus, mTOR inhibitors, are used clinically in oncology and tuberous sclerosis complex (Palavra et al., 2017). Here, MTOR is linked to breast cancer.